Every material Form 8-K Innospec has filed with the SEC since November 08, 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Innospec reported third-quarter 2026 revenue of $473.6 million, up 7% from $441.9 million a year earlier, and net income attributable to Innospec of $31.8 million, or $1.29 per diluted share, versus $12.9 million, or $0.52, a year earlier. The Board declared a semi-annual dividend of $0.94 per share, bringing the annual dividend to $1.86, a 9% increase over 2025, which shareholders of record as of November 17, 2026 will receive on November 25, 2026.
Revenue of $473.6 million, up 7% from $441.9 million in the third quarter of 2025.
GAAP diluted EPS of $1.29 versus $0.52; adjusted non-GAAP EPS of $1.29 versus $1.12.
Semi-annual dividend of $0.94 per share, payable November 25, 2026; annual dividend of $1.86, up 9%.
Cash from operating activities of $17.4 million versus $39.1 million a year earlier; cash of $251.9 million and no debt as of September 30, 2026.
Innospec reported results for the quarter ended June 30, 2026, with revenue up 12% to $491.4 million and GAAP net income of $30.8 million, or $1.25 per diluted share, compared with $23.5 million, or 94 cents, a year earlier. Adjusted non-GAAP EPS was $1.27 versus $1.26, and the company ended the quarter with $250.2 million in cash and no debt. Operating cash flow was only $7.2 million for the quarter, and the filing does not include formal guidance.
Revenue of $491.4 million, up 12% from $439.7 million a year earlier
Net income attributable to Innospec of $30.8 million, or $1.25 per diluted share, versus $1.25 year over year and 94 cents in Q2 2025
Adjusted non-GAAP EPS of $1.27 versus $1.26; cash from operations of $7.2 million before $16.5 million capital expenditure
Net cash of $250.2 million with no debt; $6.4 million spent on share repurchases in the quarter
Innospec's board increased its size from seven to eight directors and appointed Shelley Bausch as a Class II director effective July 1, 2026, with a seat on the Audit Committee. The filing describes her standard non-employee director pay, which does not involve a change in company results or outlook.
Board increased from seven to eight directors, effective June 2, 2026
Shelley Bausch appointed Class II director starting July 1, 2026, serving until the 2027 annual meeting
Bausch joins the Audit Committee as of July 1, 2026; annual cash retainer of $100,000 plus $5,000 for Audit Committee service
Expected annual equity grant value of $125,000 in February each year
Innospec reported first-quarter 2026 revenue of $453.2 million, up 3% from a year earlier, but GAAP diluted EPS fell to $1.22 from $1.31 and adjusted EPS fell to $1.05 from $1.42, with Performance Chemicals hit by a January 2026 US winter storm. The Board raised the semi-annual dividend 10% to $0.92 per share and authorized a new $75 million share repurchase program starting May 12, 2026.
Revenue $453.2 million vs. $440.8 million; Performance Chemicals operating income fell 46% to $10.7 million
GAAP diluted EPS $1.22 vs. $1.31; adjusted non-GAAP EPS $1.05 vs. $1.42
Semi-annual dividend of $0.92 per share, up 10%, payable May 29, 2026 to holders of record May 19, 2026
New $75 million buyback over three years replaces the $50 million authorization, of which about $16 million remained
Innospec reported fourth quarter and full year 2025 results. Fourth quarter revenue fell 2% to $455.6 million, while GAAP net income rose to $47.4 million from a prior-year loss that included a UK pension settlement charge. Full-year revenue fell 4% to $1.78 billion and adjusted EBITDA fell 10% to $203.0 million, so the year's operating trend was weaker even though GAAP earnings improved.
Q4 GAAP net income of $47.4 million, or $1.91 per diluted share, versus a net loss of $70.4 million, or $2.80 per share, a year earlier
Q4 adjusted non-GAAP EPS of $1.50 versus $1.41 a year ago; full-year adjusted EPS of $5.27 versus $5.92 in 2024
Full-year adjusted EBITDA of $203.0 million, down 10% from $225.2 million; net cash of $292.5 million at December 31, 2025
Innospec reported third-quarter 2025 revenue of $441.9 million, nearly flat with $443.4 million a year earlier, while net income fell to $12.9 million from $33.4 million. GAAP results include $24.4 million of net charges tied to impairments and restructuring, and the Board declared a semi-annual dividend of 87 cents per share, a 10 percent increase.
Q3 2025 net sales were $441.9 million versus $443.4 million in Q3 2024; diluted EPS was 52 cents versus $1.33
Adjusted non-GAAP EPS was $1.12 versus $1.35 a year earlier; net charges of $24.4 million cut GAAP EPS by 57 cents
Board declared a semi-annual dividend of $0.87 per share, payable November 26, 2025, to holders of record on November 18, 2025
Net cash was $270.8 million at September 30, 2025, with no debt, and $10.7 million of share repurchases were made in the quarter
Innospec reported results for the quarter ended June 30, 2025, in a press release furnished under Item 2.02. Revenue rose 1% but net income fell to $23.5 million, or 94 cents per diluted share, from $31.2 million, or $1.24, a year earlier, with the company citing lower results in Performance Chemicals and Oilfield Services.
Total revenue was $439.7 million, up 1% from $435.0 million a year earlier.
Net income was $23.5 million, or 94 cents per diluted share, versus $31.2 million, or $1.24, in the prior-year quarter.
Adjusted non-GAAP EPS was $1.26 versus $1.39 a year earlier; Performance Chemicals operating income fell 33% to $14.3 million.
The company reported net cash of $266.6 million with no debt and $8.2 million in share repurchases during the quarter.
Innospec reported first-quarter 2025 revenue of $440.8 million, down 12% from $500.2 million a year earlier, and diluted GAAP EPS of $1.31 versus $1.65. Management said tariff uncertainty will delay its recovery targets in Performance Chemicals and Oilfield Services, while the board raised the semi-annual dividend 10% to $0.84 per share.
Revenue $440.8 million vs $500.2 million; net income $32.8 million vs $41.4 million
Adjusted non-GAAP EPS $1.42 vs $1.75; Oilfield Services revenue fell 37% to $102.1 million
Semi-annual dividend of $0.84 per share, payable May 30, 2025 to holders of record May 20, 2025
Cash and cash equivalents of $299.8 million at March 31, 2025 with no debt
Innospec reported fourth-quarter 2024 net sales of $466.8 million, down 6% from a year earlier, and a net loss of $70.4 million, or $2.80 per diluted share, driven by a non-cash $155.6 million charge on the buy-out of its UK pension scheme. Excluding special items, adjusted EPS fell to $1.41 from $1.84, and full-year 2024 revenue fell 5% to $1.85 billion, so the charge and weaker sales weigh on shareholder results even as Performance Chemicals and Fuel Specialties operating income grew.
Q4 2024 net sales were $466.8 million, down 6% from $494.7 million in Q4 2023
Q4 GAAP net loss of $70.4 million, or $2.80 per diluted share, including a $155.6 million non-cash UK pension settlement charge
Adjusted EPS was $1.41 in Q4 versus $1.84 a year earlier; full-year adjusted EPS was $5.92 versus $6.09
Net cash was $289.2 million at December 31, 2024, compared with $203.7 million a year earlier
Innospec reported third-quarter 2024 results with revenue down 4% to $443.4 million and GAAP diluted EPS of $1.33, versus $1.57 a year earlier. The board also declared a semi-annual dividend of $0.79 per share, raising the full-year 2024 dividend to $1.55, a 10% increase over 2023.
Total revenue $443.4 million vs $464.1 million a year earlier; net income $33.4 million vs $39.2 million
Adjusted non-GAAP EPS $1.35 vs $1.59 a year earlier; Oilfield Services operating income fell 57% to $7.1 million
Dividend of $0.79 per share payable November 26, 2024, to holders of record on November 18, 2024
Cash and cash equivalents of $303.8 million at September 30, 2024, with no debt
Innospec reported second-quarter 2024 net sales of $435.0 million, down 9% from $480.4 million a year earlier, while net income rose to $31.2 million, or $1.24 per diluted share, from $28.9 million, or $1.16. Management said Oilfield Services sales were hit by lower production chemical activity and expects lower sales there to continue through the second half of 2024, while Performance Chemicals and Fuel Specialties improved.
Net sales were $435.0 million versus $480.4 million; net income was $31.2 million, or $1.24 per diluted share, versus $28.9 million, or $1.16.
Oilfield Services operating income fell to $7.3 million from $28.0 million, while Performance Chemicals operating income rose to $21.2 million from $9.2 million.
Adjusted non-GAAP EPS was $1.39 per diluted share, compared with $1.28 a year earlier.
As of June 30, 2024, the company had $240.2 million in cash and cash equivalents and no debt.
Innospec and its subsidiaries extended the termination date of their $250,000,000 multicurrency revolving loan facility from May 30, 2027 to May 31, 2028, effective May 20, 2024, after all lenders approved the request. The filing states that no other terms of the agreement or facility were changed, and the company paid a customary extension fee.
Innospec reported first-quarter 2024 results for the period ended March 31, 2024. Revenue fell 2% to $500.2 million, while net income rose to $41.4 million, or $1.65 per diluted share, from $33.2 million, or $1.33 per diluted share, a year earlier. The board also declared a semi-annual dividend of $0.76 per share, a 10% increase, payable May 31, 2024 to holders of record on May 20, 2024.
Revenue was $500.2 million, down 2% from $509.6 million a year earlier.
Net income was $41.4 million, or $1.65 per diluted share, versus $33.2 million, or $1.33, a year earlier.
Adjusted non-GAAP EPS was $1.75 per diluted share versus $1.38 a year earlier; cash from operating activities was $80.6 million.
Semi-annual dividend of $0.76 per share, up 10%, payable May 31, 2024 to holders of record on May 20, 2024.
Innospec's Executive Vice President and Chief Operating Officer, Dr. Philip Boon, has informed the company he will retire effective March 31, 2025. After retirement he will provide support to the company on a consultancy basis, with terms to be agreed.
Dr. Philip Boon, EVP and Chief Operating Officer, notified the company on March 31, 2024.
Retirement is effective March 31, 2025, giving the company about one year of notice.
Boon will provide support on a consultancy basis after retirement, on terms still to be agreed.
Innospec reported fourth-quarter 2023 net income of $37.8 million, or $1.51 per diluted share, up from $25.5 million, or $1.02, a year earlier, while quarterly revenue fell 3% to $494.7 million. For the full year, revenue was $1.95 billion, down less than 1%, and GAAP diluted EPS rose to $5.56 from $5.32, so reported profit grew on slightly lower sales.
Q4 2023 revenue $494.7 million, down 3% from $510.7 million
Q4 GAAP diluted EPS $1.51 vs $1.02; adjusted non-GAAP EPS $1.84 vs $1.20
Full-year 2023 revenue $1.95 billion, down less than 1%; GAAP diluted EPS $5.56 vs $5.32
Net cash of $203.7 million at December 31, 2023, after funding the QGP acquisition
Innospec reported third-quarter 2023 net sales of $464.1 million, down 10% from $513.0 million a year earlier, while GAAP diluted EPS rose to $1.57 from $1.55. Adjusted non-GAAP EPS fell to $1.59 from $1.74. The board also declared a semi-annual dividend of $0.72 per share, bringing the 2023 annual dividend to $1.41, a 10% increase over 2022.
Net sales were $464.1 million versus $513.0 million a year earlier; Performance Chemicals fell 9%, Fuel Specialties 5% and Oilfield Services 14%.
Net income was $39.2 million, or $1.57 per diluted share, versus $38.7 million, or $1.55, a year earlier; adjusted EPS was $1.59 versus $1.74.
Cash from operating activities was $58.1 million; cash and cash equivalents were $207.2 million with no debt as of September 30, 2023.
The $0.72 dividend will be paid November 27, 2023 to holders of record on November 20, 2023.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Innospec filing is on SEC EDGAR ↗. 8-K briefs of other companies →